Cargando…

Immunotherapy in triple-negative breast cancer: A literature review and new advances

Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and historically has limited treatment options. It has a high probability of disease recurrence and rapid disease progression despite adequate systemic treatment. Immunotherapy has emerged as an important alternative in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valencia, Guillermo Arturo, Rioja, Patricia, Morante, Zaida, Ruiz, Rossana, Fuentes, Hugo, Castaneda, Carlos A, Vidaurre, Tatiana, Neciosup, Silvia, Gomez, Henry L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966508/ https://www.ncbi.nlm.nih.gov/pubmed/35433291 http://dx.doi.org/10.5306/wjco.v13.i3.219

Ejemplares similares

Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer
por: Morante, Zaida, et al.
Publicado: (2023)

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
por: Rabanal, Connie, et al.
Publicado: (2017)

PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
por: Valencia, Guillermo Arturo, et al.
Publicado: (2021)

The current situation regarding the availability and accessibility of anticancer drugs for breast cancer in the Peruvian public health systems
por: Valencia-Mesías, Guillermo, et al.
Publicado: (2021)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease
por: Pinto, Joseph A, et al.
Publicado: (2016)

Renal liposarcoma: case report and review of systemic treatment
por: Rioja, Patricia, et al.
Publicado: (2021)

Why natural killer cells in triple negative breast cancer?
por: Abdel-Latif, Mustafa, et al.
Publicado: (2020)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience
por: De-la-Cruz-Ku, Gabriel, et al.
Publicado: (2020)

Breast cancer subtype and clinical characteristics in women from Peru
por: Zavala, Valentina A., et al.
Publicado: (2023)

Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor
por: Rao, Zhou-Zhou, et al.
Publicado: (2023)

LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor
por: Wang, Y, et al.
Publicado: (2013)

Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity
por: Iranzo, Isabel, et al.
Publicado: (2018)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

Immunotherapy for pancreatic cancer
por: Yoon, Jai Hoon, et al.
Publicado: (2021)

Tsunami of immunotherapy reaches mesothelioma
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2022)

Immunotherapy for recurrent hepatocellular carcinoma
por: Bhatt, Ahan, et al.
Publicado: (2023)

Immunotherapy for advanced gastric cancer
por: Leowattana, Wattana, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Targeting cytotoxic T lymphocytes for cancer immunotherapy
por: Maher, J, et al.
Publicado: (2004)

Immunotherapies in sarcoma: Updates and future perspectives
por: Ghosn, Marwan, et al.
Publicado: (2017)

Targets of immunotherapy for hepatocellular carcinoma: An update
por: Rai, Vikrant, et al.
Publicado: (2022)

Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021)

Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
por: Araujo, Jhajaira M., et al.
Publicado: (2018)

T-regulatory cell modulation: the future of cancer immunotherapy?
por: Nizar, S, et al.
Publicado: (2009)

Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
por: Yan, Cong, et al.
Publicado: (2019)

Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020)

Combined targeted therapy and immunotherapy for cancer treatment
por: Guo, Cheng-Xiang, et al.
Publicado: (2021)

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
por: Chen, Pu, et al.
Publicado: (2021)

Research status on immunotherapy trials of gastric cancer
por: Liang, Chao, et al.
Publicado: (2021)

Implication of gut microbiome in immunotherapy for colorectal cancer
por: Koustas, Evangelos, et al.
Publicado: (2022)

Progress in immunotherapy for neuroendocrine neoplasm of the digestive system
por: Pan, Wei-Xuan, et al.
Publicado: (2023)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018)

Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
por: Luo, Yi, et al.
Publicado: (2022)

Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
por: Mandlik, Deepa S, et al.
Publicado: (2023)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Exploring the food-gut axis in immunotherapy response of cancer patients
por: Russo, Edda, et al.
Publicado: (2020)

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
por: Sarantis, Panagiotis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dpgfudollnol1lke90t8het1f4